Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2653-2661

  Alewine, Christine ^a   Xiang, Laiman ^a   Yamori, Takao ^b   Niederfellner, Gerhard ^c   Bosslet, Klaus ^c   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^c LMR Penzberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MESOTHELIN; PACLITAXEL; RG 7787; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; RG7787;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER SURGERY; CELL KILLING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GASTRIC CANCER CELL LINE; IC50; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; SOLID TUMOR; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; NUDE MOUSE; STOMACH NEOPLASMS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; MICE; MICE, NUDE; STOMACH NEOPLASMS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918775119     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0132     Document Type: Article

References (30)

1. Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, et al. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther 2013;12:48-57.
2. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler- Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with Hairy Cell Leukemia. J Clin Oncol 2012;30:1822-8.
3. Wayne AS, Bhojwani D, Silverman LB, Richards K, Stetler-Stevenson M, Shah NN, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric Acute Lymphoblastic Leukemia (ALL). Blood 2011;118:248.
4. Kreitman RJ, Singh R, Stetler-Stevenson M, Waldmann TA, Pastan I. Regression of Adult T-cell Leukemia with anti-CD25 recombinant immunotoxin LMB-2 preceded by chemotherapy. Blood 2011;118: 2575a.
5. Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem 2013;13:276-80.
6. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patientswith mesothelin- expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
7. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
8. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, et al. Major cancer regressions in mesothelioma after treatment with an antimesothelin immunotoxin and immune suppression. Science Transl Med 2013;5:208ra147.
9. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 2012;109:11782-7.
10. th Annual Meeting of the AACR; 2014:4510 (abstr) .
11. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40.
12. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod pathol 2003;16:192-7.
13. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005;13:243-7.
14. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
15. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
16. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 2012;133: 799-804.
17. Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, et al. Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 2012;105:195-9.
18. Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 2012;107: 137-42.
19. Ito T, Kajino K, Abe M, Sato K, Maekawa H, Sakurada M, et al. ERC/ mesothelin is expressed in human gastric cancer tissues and cell lines. Oncol Rep 2014;31:27-33.
20. Kelly RJ, Pastan I, Cowan ML, Montgomery E, Hassan R, Alewine CC, et al. Mesothelin expression in patients as a novel target in gastric cancer. J Clin Oncol 32, 2014 (suppl 3; abstr 61).
21. Motoyama T, Hojo H, Watanabe H. Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn 1986;36: 65-83.
22. Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 2007;104: 17099-104.
23. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004;248:503-18.
24. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumorbearing mice. Clin Cancer Res 2006;12:4695-701.
25. Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 2008;14: 7981-6.
26. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res 2010;70:1082-9.
27. Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res 2012;32:5151-8.
28. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20.
29. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009;113:3792-800.
30. Hollevoet K, Mason-Osann E, Liu XF, Imof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 2014;13:2040-9